OSTX logo

OS THERAPIES INC

OSTXNYSE AMERICAN
🏆 #4240 by market capUS Equity
$128.28▼ $7.34 (−5.72%)
Simulated price
🔔
Track OSTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.7%
7d▲ 7674.5%
14d▲ 7272.4%
30d▲ 7513.1%
ytd▲ 9095.7%
1y▲ 6546.6%
🏦Market Cap
$75M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$126.23 – $129.31
52-Week Range
$1.15 – $2.25
Volume
$2.43B
Avg Volume
$2.82B
Shares Outstanding
45.5M
Next Earnings
Nov 27, 2026

Fundamentals Snapshot

Annual Revenue
$5M
Last Q Revenue
$1M
P/E Ratio
-1.5
P/S Ratio
0.0x
EPS (TTM)
$-0.90
Dividend Yield
0.00%
Dilution (1yr)
−76.4%

Why Investors Own OSTX

  • ✓High-growth profile — revenue up +12.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 58% gross margin and 16% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OSTX logo

OS THERAPIES INC

OSTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$29M▲ +321.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$14.2B▲ +195423.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
29.3M▼ −76.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$270K▼ −$5M YoY
StockOtter · stockotter.space

About OS THERAPIES INC

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$146.21
▲ +14.0% Upside
High Target$180.20
Low Target$135.39
Based on 28 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

OS THERAPIES INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift OSTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

OS THERAPIES INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.